Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection

ABSTRACT: Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection

PROVIDER: PRJNA609296 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11197900.fastq.gz	Fastqsanger.gz
	SRR11197847.fastq.gz	Fastqsanger.gz
	SRR11197848.fastq.gz	Fastqsanger.gz
	SRR11197849.fastq.gz	Fastqsanger.gz
	SRR11197850.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 54

Similar Datasets

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (neutrophils)

Project description:Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (neutrophils)

| PRJNA609306 | ENA

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (neutrophils)

Project description:Treating inflammatory diseases with Janus kinase 1/2 (JAK1/2) inhibitors bears the risk that patients acquire viral infections due to unwanted immune suppression. Tyrosine kinase 2 (TYK2), a JAK family member, is required for type I interferon (IFN-α/β) signaling, but its role in type III IFN (IFN-λ) signaling is still under debate. We found that the selective TYK2 inhibitor BMS-986165 blocked potentially noxious type I IFN signaling without altering IFN-λ-mediated gene expression. We show that epithelial cells do not require TYK2 for IFN-λ-mediated signaling or antiviral protection. Lack of TYK2 diminished IFN-α-induced protection against lethal influenza virus infection of mice, but did not impair IFN-λ-mediated antiviral protection. Our findings suggest that selective TYK2 inhibitors likely represent a superior treatment option for type I interferonopathies than broadly acting JAK1/2 inhibitors, as selective TYK2 inhibitors may counteract inflammatory responses without abolishing the beneficial antiviral effects of IFN-λ.

2021-04-09 | GSE146103 | GEO

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (airway epithelial cells)

Project description:Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (airway epithelial cells)

| PRJNA609307 | ENA

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection (airway epithelial cells)

2021-04-09 | GSE146102 | GEO

Pharmacological inhibition of tyrosine kinase 2 preserves interferon-λ-mediated protection

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-04-09 | GSE146104 | GEO

Lambdavirus lambda

Project description:Lambdavirus lambda

| PRJNA388730 | ENA

Lambdavirus lambda

Project description:Speciation phage lambda

| PRJNA353945 | ENA

Lambdavirus lambda

Project description:Lambdavirus lambda Genome sequencing

| PRJNA274640 | ENA

Lambdavirus lambda

Project description:Lambda phage locus mutagenesis

| PRJNA326138 | ENA

Total gene expression analysis of LMP2A/λ-MYC and λ-MYC tumors

Project description:We have developed a transgenic mouse model for Epstein-Barr virus-associated Burkitt's lymphoma. Transgenic mice that express LMP2A and MYC in B cells develop spontaneous lymph node tumors at different rates. Tumor onset occurs at approximately 40-60 days in LMP2A/λ-MYC mice and at 100-200 days in λ-MYC mice. This study compared total gene expression in the tumor cells from each genotype, as well as in B cells isolated from 3 week old mice prior to tumor onset. Comparison of total gene expression in tumor cells from LMP2A/λ-MYC and λ-MYC transgenic mice identified a short list of differentially expressed genes. Comparison of gene expression in B cells from the spleens of 3 week old mice, in contrast, identified a 10-fold increase in the number of differentially expressed genes.

2011-10-26 | GSE26918 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data